Compositions and methods for tumor immunotherapy
US12246031B2 · kind B2 · utility
0Cited by
79References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2019 |
| Grant date | Mar 11, 2025 |
| Priority date | — |
| Expiry date | Jun 15, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2795/18141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.